Abstract | AIM: We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug for treating idiopathic OAB. METHODS: A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of onabotulinumtoxinA for the treatment of idiopathic OAB. The search included the following databases: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. RESULTS: Eight publications involving a total of 1,320 patients were used in the analysis, including six RCTs that compared onabotulinumtoxinA with placebo. OnabotulinumtoxinA significantly decreased the mean number of urinary incontinence (UI) per day -2.77 versus -1.01 (the standardized mean difference (SMD) = -1.68, 95% CI = -2.06 to -1.31, P < 0.00001); the mean number of micturitions per day -1.61 versus -0.87 (SMD = -1.82, 95% CI = -2.61 to -1.02, P < 0.00001); maximum cystometric capacity (MCC) 91.39 versus 32.32 (SMD = 63.82, 95% CI = 38.14 to 89.50, P < 0.00001) and volume voided 44.29 versus 7.36 (SMD = 33.05, 95% CI = 22.45 to 43.66, P < 0.00001) versus placebo and 29.20% versus 7.95% of patients became incontinence-free (odds ratio [OR] = 4.89, 95% confidence interval [CI] = 3.11 to 7.70, P < 0.00001). Safety assessments primarily localized to the urinary tract indicated onabotulinumtoxinA were often associated with complications resulting from postvoid residuals (PVR; P < 0.00001), urinary tract infections (UTI; P < 0.00001) and clean intermittent catheterization (CIC; P < 0.00001). CONCLUSION: This meta-analysis indicates that onabotulinumtoxinA to be an effective treatment for idiopathic overactive bladder symptoms with side effects primarily localized to urinary tract.
|
Authors | Yuanshan Cui, Xin Zhou, Huantao Zong, Huilei Yan, Yong Zhang |
Journal | Neurourology and urodynamics
(Neurourol Urodyn)
Vol. 34
Issue 5
Pg. 413-9
(Jun 2015)
ISSN: 1520-6777 [Electronic] United States |
PMID | 24676791
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Copyright | © 2014 Wiley Periodicals, Inc. |
Chemical References |
- Acetylcholine Release Inhibitors
- Botulinum Toxins, Type A
|
Topics |
- Acetylcholine Release Inhibitors
(therapeutic use)
- Botulinum Toxins, Type A
(therapeutic use)
- Humans
- Treatment Outcome
- Urinary Bladder, Overactive
(drug therapy)
- Urinary Catheterization
(adverse effects)
- Urinary Retention
(chemically induced)
- Urinary Tract Infections
(chemically induced, etiology)
|